Breaking News

NightHawk Begins Work on Mfg. Agreement for Leading University

Scorpius subsidiary to manufacture novel biologic targeting substance use disorder.

NightHawk Biosciences, an integrated contract development and manufacturing organization (CDMO), reported that Scorpius BioManufacturing has commenced work on a contract that it was awarded by a leading university to develop and manufacture a novel biologic targeting substance use disorder, which includes drug, alcohol, and opioid addiction. Jeff Wolf, CEO of NightHawk, said, “We are honored to have been awarded this multi-million-dollar contract by one of the foremost research universities i...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters